BSE filing, BSE: 543828. Summary written from the filing by ALFA Finder's alert engine.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹37.61
- Market cap
- ₹905.1 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 38.8×Sector 34.1×
- Promoter holding
- 57.81%-1.12% QoQ
- FII holding
- 21.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Board Meeting Date
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma Industries SME to Main Board Migration
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.
Sudarshan Pharma Industries Other Announcement
Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sudarshan Pharma Industries Merger & Restructuring
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries Merger & Restructuring Worth ₹1.4 Cr
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
- Value
- ₹1.40 Cr
Sudarshan Pharma Industries Annual General Meeting
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr